And in gastric adenocarcinoma, high MFAP2 expression was significantly correlated with the first progression and post-progressive survival shortening; the overall and disease-free survivals were shorter in patients with increased MFAP2 expression (26, 27). Here, MFAP2 is linked to gastric adenocarcinoma.